Results Announcement Date – Reliance on NZX Class Waiver

NZX Announcement

29 May 2020

Results Announcement Date – Reliance on NZX Class Waiver
Truscreen Limited (NZX:TRU) (Truscreen or “Company”) advises that the Company’s preliminary results
for the year ended 31 March 2020 will be released on 29 June 2020.
Truscreen is relying on the NZX Class Waiver from Listing Rule 3.5.1 dated 19 March 2020 which
provides issuers with an additional 30 days to release their full year results announcement.
Truscreen expects to also release its annual report on 29 June 2020, it will not be relying on the class
waiver from Listing Rule 3.6.1 which allows an additional two months for the preparation and release
of an issuer’s annual report.


Guy Robertson
Chief Financial Officer

- ENDS -


For more information, visit www.truscreen.com or contact:

TruScreen
Victoria Potarina
Chief Executive Officer
victoriapotarina@truscreen.com


Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen is a Cervical Cancer Screening Device which
offers the latest technology in cervical screening,
providing real-time, accurate detection of pre-
cancerous and cancerous cervical cells to help improve
the health and well-being of women around the world.
TruScreen’s real-time cervical cancer technology
utilises a digital wand which is placed on the surface of
the cervix to measure electrical and optical signals from
the surrounding tissues. A sophisticated proprietary
algorithm framework is utilised to detect pre-cancerous
change, or cervical intra-epithelial neoplasia (CIN), by
optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing
issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and
the need for supporting laboratory infrastructures. As such, TruScreen’s target market is low-
and middle-income countries where no large-scale cervical cancer screening programs and
infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen’s cervical
cancer screening device is CE-marked and certified for use throughout Europe and CFDA-
approved for sale in China. The global market potential for TruScreen is significant.

For more information, visit our website at www.truscreen.com

Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen- ultra-
video/